ICON Announces the Appointment of Ms. Julie O’Neill to Board of Directors & Confirms the Retirement of Professor Dermot Kel...
July 24 2019 - 06:05AM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug and device
development and commercialisation services to the pharmaceutical,
biotechnology and medical device industries, today announced the
appointment of Ms. Julie O’Neill as a non-executive director.
Ms. O’Neill is an accomplished pharmaceutical leader and
advisor. Ms. O’Neill was formerly Executive Vice President, Global
Operations of Alexion Pharmaceuticals, Inc., where she was
responsible for global manufacturing operations and expanding and
improving supply chain and quality operations in the US, Europe,
and Asia. Before joining Alexion, Ms. O’Neill was Vice President of
Operations and General Manager for Ireland at Gilead Sciences and
earlier in her career, Ms. O'Neill held leadership positions in
operations, manufacturing and quality functions at Burnil
Pharmacies and Helsinn Birex Pharmaceuticals.
Ms. O’Neill serves as a Board Member of DBV Technologies and
Hookipa Pharma Inc. and is also on the Board of Ireland’s National
Institute for Bioprocessing Research and Training. Ms. O’Neill
holds a Bachelor of Science in Pharmacy from Trinity College
Dublin, a Masters of Business Administration from University
College Dublin and is a Chartered Director of The Institute of
Directors in Ireland.
“I am very pleased that Julie has joined the board," commented
Mr. Ciaran Murray, Non-Executive Chairman of ICON plc. "Her
leadership positions in global pharmaceutical organisations will
bring invaluable experience to the ICON Board.”
ICON has also announced the retirement of Professor Dermot
Kelleher and Mr. Declan McKeon as non-executive directors.
Professor Dermot Kelleher, a Fellow of the Academy of Medical
Sciences, joined the ICON Board in May 2008 and has served on a
number of Board committees during his 11 years of service.
Mr. McKeon, a former partner in PWC Ireland, joined the ICON
Board in April 2010 and served as acting Chairman from April 2016
until March 2017. In addition, he served as the Lead Independent
Director from March 2017 to December 2018.
“I would also like to thank Dermot and Declan for their long and
distinguished service to ICON and for their wise counsel, valuable
insight and important contributions to the Board and to the
committees on which they have served.” commented Mr. Ciaran
Murray.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug and device development and
commercialisation services to pharmaceutical, biotechnology,
medical device and government and public health organisations. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 98
locations in 40 countries and has approximately 14,400
employees.
Further information is available at www.iconplc.com.
Source: ICON plc
All at ICON.
ICON/ICLR-F
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190724005302/en/
Investor Relations 1 888 381 7923 or Brendan Brennan Chief
Financial Officer + 353 1 291 2000
Jonathan Curtain Vice President Corporate Finance and Investor
Relations + 353 1 291 2000
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Feb 2024 to Mar 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2023 to Mar 2024